基因组分析识别预测实体瘤患者血栓栓塞风险的体细胞突变
Venous thromboembolism (VTE) associated with cancer (CAT) is a well-described complication of cancer and a leading cause of death in patients with cancer.…
要点
- STK11突变与癌症相关VTE风险增加相关(HR 2.12)。
- KRAS、KEAP1、CTNNB1、CDKN2B和MET突变与VTE风险增加相关。
- 克隆性造血的存在与VTE风险增加无关。
核心结论
- 实体瘤中STK11、KRAS、CTNNB1、KEAP1、CDKN2B和MET的体细胞突变与VTE风险增加相关。
- SETD2突变与癌症相关VTE风险降低相关。
- 克隆性造血与VTE风险增加无关。
研究设计与样本
- 研究终点定义为首次发生癌症相关肺栓塞和/或下肢近端/远端深静脉血栓。
- 采用病因特异性Cox比例风险回归,调整相关临床协变量。
临床怎么用
- 实体瘤患者中检测STK11、KRAS、CTNNB1、KEAP1、CDKN2B和MET突变可能有助于识别VTE高风险患者。
- 对于携带上述突变的患者,可考虑加强血栓预防或监测。
局限性
- 需要进一步分析验证这些发现,并识别个体肿瘤类型特有的其他分子特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venous thromboembolism (VTE) associated with cancer (CAT) is a well-described complication of cancer and a leading cause of death in patients with cancer. The purpose of this study was to assess potential associations of molecular signatures with CAT, including tumor-specific mutations and the presence of clonal hematopoiesis. We analyzed deep-coverage targeted DNA-sequencing data of >14 000 solid tumor samples using the Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets platform to identify somatic alterations associated with VTE. End point was defined as the first instance of cancer-associated pulmonary embolism and/or proximal/distal lower extremity deep vein thrombosis. Cause-specific Cox proportional hazards regression was used, adjusting for pertinent clinical covariates. Of 11 695 evaluable individuals, 72% had metastatic disease at time of analysis. Tumor-specific mutations in KRAS (hazard ratio [HR], 1.34; 95% confidence interval (CI), 1.09-1.64; adjusted P = .08), STK11 (HR, 2.12; 95% CI, 1.55-2.89; adjusted P < .001), KEAP1 (HR, 1.84; 95% CI, 1.21-2.79; adjusted P = .07), CTNNB1 (HR, 1.73; 95% CI, 1.15-2.60; adjusted P = .09), CDKN2B (HR, 1.45; 95% CI, 1.13-1.85; adjusted P = .07), and MET (HR, 1.83; 95% CI, 1.15-2.92; adjusted P = .09) were associated with a significantly increased risk of CAT independent of tumor type. Mutations in SETD2 were associated with a decreased risk of CAT (HR, 0.35; 95% CI, 0.16-0.79; adjusted P = .09). The presence of clonal hematopoiesis was not associated with an increased VTE rate. This is the first large-scale analysis to elucidate tumor-specific genomic events associated with CAT. Somatic tumor mutations of STK11, KRAS, CTNNB1, KEAP1, CDKN2B, and MET were associated with an increased risk of VTE in patients with solid tumors. Further analysis is needed to validate these findings and identify additional molecular signatures unique to individual tumor types.
引用
- Dunbar A, Bolton KL, Devlin SM, et al. Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood. 2021. PMID: 33270827. doi:10.1182/blood.2020007488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。